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Introduction
Radiopharmaceuticals, also known as radiotracer, are molecules labelled with radioactive nuclides used
to study the insight of the human body noninvasively and in vivo; this means that we are able to
have a look at what’s happening inside patient’s body at molecular level using appropriate diagnostic
techniques, such as PET (Positron Emission Tomography). In the era of personalized medicine,
radiopharmaceuticals are a powerful tool even for therapy [2].
Goal of this work is to try to assess the amount of radiation that a human would absorb by exposure to
51Mn and 52Mn starting from animal data taken from [4] and [19], both of them employing MnCl2 as
radiopharmaceutical. Although using Mn in its ionic form hasn’t very good biodistribution properties
and shows some side-effects [9], many studies are conducted exploiting it and gathered data on it
since it’s the easiest manganese-based radiopharmaceutical to produce; yet, there are no dosimetric
evaluation found in literature. In particular, 52Mn is a long-lived isotope (t1/2 = 5.591 days) thought
to be employed in order to study biological processes and molecules with slow biodistribution (such as
antibodies). It has been chosen because it is the only radionuclide with 1 < Z < 92 having positron-
emitting nuclear properties that resemble a lot those of 18F (so that it can be employed as radiotracer
for PET imaging) and it has very useful paramagnetic properties that makes it suitable to be used as
MRI contrast agent. As a matter of fact there are experiments [12] [9] that shows both pros and cons of
this metal, focusing their attention on the quality of the image it can produce in a possible MultiModal
Imaging approach in diagnostic Nuclear Medicine that combines both PET/MRI; in this way it is
possible using different diagnostic informations, improving the understanding of clinical conditions.
A dosimetric assessment of these isotopes is important also because of the upcoming research project
METRICS (Multimodal pET/mRi Imaging with Cyclotron-produced 52/51Mn and stable paramagnetic
Mn iSotopes) that will take place also at INFN Legnaro National Laboratory that aims at produce
as pure as possible 52Mn through different possible reactions.
In the first chapter basic physical properties of these isotopes are presented and subsequently, after a
brief introduction about the working principles of the two imaging modality that are going to exploit
51Mn and 52Mn, their use as radiopharmaceuticals (and side effects) will be discussed. Afterwards, in
third chapter, basic concepts of dosimetry will be introduced in order to apply them to data gathered
in literature and evaluate the energy released by the radiation within the human body.
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Chapter 1
Mn radioisotopes physical properties
The Mn isotopes that are going to be discussed and analyzed in the thesis are 52Mn and 51Mn; in
this chapter physical aspects and properties of this two radionuclides will be presented.
1.1 Decay scheme, positron energy and range
The 52Mn decay to stable 52Cr by electron capture (70.4%) and positron emission (29.6%) and has an
half-life of 5.591 days. In order to perform dosimetric evaluations of the Mn isotopes it is necessary
to know how much energy would be released by the emitted positron in the decay reaction and how
much lenght it would travel in the body before it annihilates with an electron. As for the energy,
from Fermi’s β+ decay theory we know that this is a 3-body process so the positron energy is not
completely determined from the masses of the particles involved in the decay (in the center of mass
reference system); this means that in practice it’s helpful to consider its possible maximum energy
(when νe is produced at rest) known as End point energy or Q-value that is Q = 575.5 keV . Sometimes
even emitted positron mean energy can be taken in account Emean = 244.6keV [1] [3].
An important physical quantity to asses the distance traveled by a given particle in a medium is the
range R that is defined as the length that it covers until it stops
R =
∫ Etot
0
(
dE
dx
)−1
dE
where dEdx is the energy loss per unit of length. This value gives information about the intrinsic loss
of spatial resolution that is achievable in Nuclear Medicine imaging techniques like PET that exploit
e+e− annihilation to detect the radiopharmaceutical.
Although 52Mn gamma emission scheme is pretty complicated (19 possible different emissions allowed)
there are only three photons with high relative intensity that can be detected easily and they are showed
in Figure 1.1; they are emitted in coincidence with the positron and they are γ1 = 744 keV (90.0 %),
γ2 = 936 keV (94.5 %) and γ3 = 1434 keV (100.0 %). Positron emitter nuclei are important for the
use of 511 keV annihilation γs for PET scans and because of the emissions of previous high energy
photons, it would be better to select a narrow window in the detector acquisition system in order
to not reveal them. Actually some of these photons could be detected anyway because they could
scatter inside the patient’s body or inside the detector creating new photons with an energy that fits
the restricted window of acceptance, producing false events. Also, these photons increases the energy
absorbed by the body when using 52Mn-based radiopharmaceuticals.
The other nuclide that will be analyzed farther is 51Mn (t1/2 = 46.2min, Emean = 970.2keV ) that
decay β+ to unstable 51Cr with a probability of 97.1 %. Even though there are no prominent gamma
emissions (> 1%), additional dose contribution comes from the daughter nucleus 51Cr that emits a
320 keV gamma ray in 10% of the decays [4].
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Figure 1.1: Simplified decay scheme of 52Mn with only relevant gamma rays
The three γs are emitted nearly in coincidence with the positron
1.2 Production
As for the production of the two Mn isotopes there are some basic common procedures: first of all
it’s necessary to study the nuclear reactions with highest cross section and lowest amount of isotopic
impurities (that cannot be eliminated by chemical separation) and then to find a chemical technique
that allows to separate the requested nuclide from all the other elements produced in the target. The
search for a good separation method must take in account the radioactive half-life of the radioisotopes
since it could be quite small (e.g. t1/2 = 46.2min for 51Mn) and this could lead to a low final yield
of the product.
52Mn can be produced through different nuclear reactions:
• 51V (3He, t) 52Mn via this one a large quantity of impurities are produced (i.e.49V , 51Cr 52Cr)
that actually can be easily removed from the sample with chemichal techniques [1];
• natCr(3He, t) 52Mn that yet produces a remarkable amount of 53Mn and thanks to its very long
half-life (∼ 106years) this reaction has not been investigated farther [1];
• 52Cr(p, n) 52Mn is suitable for production in small cyclotrons although in this reaction it is often
used natCr because of the high abundance of 52Cr (83.7%); the use of natural chromium could
be favorable for its lower cost than pure 52Cr target even though there is a slight decrease of
the cross section and the production of other isotopic contaminats (51Mn, 52mMn). [1]
Still there are more possible reactions (e. g. 52Cr(d, 2n) 52m/gMn) that can be employed, but the
fundamental requirements are high cross section and radionuclidic purity, in order not to have con-
taminations that could limit the use of 52Mn as radiopharmaceutical.
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Chapter 2
Medical application: Mn-based
radiopharmaceuticals
Radiopharmaceuticals are radioactive molecular probes that point out specific biological structures
(cell receptors, proteins, enzymes) in order to detect their presence and distribution throughout the
body of the subject being studied or destroy selected target by using radiation emitting nuclei (this
radiation could be alpha particles or high energy positrons) . As for diagnostic application of ra-
diopharmaceutical it’s useful the definition given by the Society of Nuclear Medicine: “Diagnostic
radiopharmaceuticals are substances that contain radionuclides that emit penetring radiations. [...]
Dynamic and static images of the distribution of the radiopharmaceutical within the body can be
obtained using a gamma camera or other suitable instrument appropriate for the radiopharamceutical
being imaged, e.g. positron-emitting radiopharmaceutical” [6]. As well as radiopharmaceutical, molec-
ular probes can be anything that once injected into the body and linked to an appropriate molecule
can give information about its position by creating (under certain conditions) a signal detectable from
the outside: this is the case, for examples, of paramagnetic metals used as contrast media to improve
imaging with Magnetic Resonance technique in order to have a better contrast between selected tis-
sues and the surrounding ones. This means that in general this molecular probes are made with the
same basic entities: a structure that enables the probes to interact in vivo with the organism 1 and
the signalling part that allows the revelation from outside. A schematic picture of this mechanism
is shown in Figure 2.1, where it is possible to see that a linker is needed to connect the previous
components.
2.1 PET and MRI imaging overview
Up to now we’ve seen what a radiopharmaceutical, or more generally speaking a molecular probe,
is and how we can use it to gain informations for diagnostic purpose. Obviously different nuclei
(positron emitting or paramagnetic ones) need different tools to be detected in the laboratory: these
are PET and MRI that are techniques widely used all over the world in daily diagnosis routine and
the developement of better instrumentation and improvement passes also through the search for new
elements to be used. These elements will be later exploited as radiotracer because of their particular
type of radiation emitted, as contrast media because of their paramagnetic properties or even both
simultaneously: one of the reasons why 51Mn and 52Mn have been studied in the last decades is
that they show very good properties in possible applications for a joint PET/MRI imaging tool. Basic
working principles of the detecting part and the different physical phenomena underlying these imaging
tools are going to be briefly analyzed in the following sections, in order to undestand how they can
provide helpful information and the reasons why Mn is an interesting tool.
1In other words it can be a particular pharmaceutical chosen accordingly to the target it has to reach or a molecule
that has a pivotal role in some biological process , in order to obtain information about it
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site. Data from [1]. 
 
In fact, according to reports of the United Nations Scientific Committee on the Effects of 
Figure 2.1: Radiopharmaceutical’s schematic structure (picture taken from [6])
2.1.1 PET
PET imaging is based on the utilization of unstable isotopes of a nucleus that decay by emission of a
positron (β+decay); once this nucleus is bound to a molecule in order to create radiopharmaceuticals
it can be injected in the body. At this point, while decaying, the emitted positron will cover a length
inside the cell proportional to it’s energy (see previous definition of Range) and as soon as it is at rest
in the laboratory frame it will annihilates with an electron producing two photons at Eγ = 511 keV ,
same mass of an electron/positron. These photons will be produced at the same time and will travel
in opposite directions due to quadrimomentum conservation and will be detected in coincidence2 by a
circular array of detector (usually scintillator) put around the patient’s body. Once they get detected
it is possible to localize their source along a straight line of coincidence (also called the line of response,
or LOR) and to use these data for image reconsruction. Modern PET system can better localize the
point of origin of the annihilation event and get a better image resolution with a method called Time
of Flight technology using the simple kinematical relation (the speed of light and the time interval
between the arrival of the two γs is known) D = c∆t/2 [7] . In Table 2.1 there is a comparison
OR ALSO IN #URIE #I	 WHERE  #I s
Nucleus
< 1 mm
Photon
Photon
Annichilation
Radionuclides used in PET (most common 
Ga) emit positrons 
because they are in a particular unstable nuclear 
OR ALSO IN #URIE #I	 WHERE  #I s
Figure 2.2: Annihilation of a positron with an electron (left) and its detection (right)
between Mn isotopes and the most used radionuclide, 18F which displays very competitve properties
with respect to others. For example 51Mn emits positron at very high energy and this made the
2Actually one should search for “true” coincidences since possible contaminations due to scatter events or random
coincidences could occur generating a wrong image
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spatial resolution very poor (few millimiters traveled before annihilation make hard to go back to the
original position of the radiopharmaceutical) while 18F and 52Mn travel less than a millimiter.
Table 2.1: Comparison between Mn isotopes and other studied radionuclides for PET (data taken from [8])
Radionuclide Half-life Endpoint energy (MeV ) Intrinsic loss of resolution (mm)
18F 1.83h 0.635 0.7
51Mn 46.2min 2.21 2.9
52Mn 5.59 days 0.575 0.63
52mMn 21.1min 2.63 3.5
64Cu 12.7h 0.657 0.73
89Zr 3.27 days 0.897 1.0
The physical half-life is another important parameter to look at: 52Mn has a quite long one so that it
is possible to get various images acquired through PET even days after the initial administration [3];
this could be very useful if tracing molecules with long biological life (such as antibodies). Therefore,
in this case, it should be used a radiopharmaceutical with a proper time of retention in organs in order
not to expose the patient to very high doses, for example this is what happens with MnCl2.
Very different scenarios for 18F and 51Mn that will stay in the organism much lesser time and are
exploited to study fast processes (for example [18F ][FDG] is used to detect cancer cells and exploits
the fast glucose metabolism).
2.1.2 MRI
MRI imaging relies on a different physical mechanism that does not require radiation or unstable
nuclei that is the coupling of a magnetic moment with a magnetic field. The human body is made
of water (H2O) and fat and this means that here is a lot of hydrogen in our body. Hydrogen is the
simpliest atom of the periodic table, made by one proton and one electron: the proton is a particle
that possesses an intrinsic angular momentum called spin and sp = ~/2 (the proton is a 1/2 spin
particle). The spin of a particle is a quantum phenomen that has no classical equivalent and it has
been observed experimentally that it’s value (along any axis of a frame) is always ±1/23 and that,
until it is measured, it can have both value with equal probability. In other words, the proton does not
have a value for its spin until it’s measured and this lead to an important macroscopic consequence:
the mean magnetic field produced by this layout of spins is null. The spin of proton is responsible
for nuclear magnetic moment of the particle itself that, like any classical magnetic dipole, turns to
align to any external magnetic field in order to minimize the energy of the system. In MRI this
mechanism is exploited and the patient is exposed to an intense external magnetic field that gives rise
to a magnetization field generated by coherent orientation of the nuclear magnetic moment of every
proton, even though it is too small to be detected. That’s why the technique of resonance is used: a
mechanism that generate a RadioFrequency is applied to the target zone so that the amplitude of the
oscillations of the spins4 increases and the variation in time of this oscillating magnetization field is
detectable from the instrumentation. [7]
This technique can be enhanced by the use of metals called paramagnetic: these materials’ molecules
show an intrinsic magnetic dipole that could aligns in the same direction of the external magnetic field
increasing its intensity; therefore it’s evident that they can be used to have better contrast in specific
tissues where they have been absorbed making the image obtained more clear and sharp than what
gained with standard technique.
3in unit of the reduced Planck constant ~
4if the spin is not perfectly aligned to the magnetic field it will start to precede around it, creating an oscillatory
motion
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2.2 Mn application
We want to know at this point what are the common features of 51Mn and 52Mn and why they are so
promising and inviting in the field of Nuclear Medicine for diagnostic purposes. The reason is that they
show many improvement if used in MRI and PET with respect to other agents or radiopharmaceuticals
and this means that they can easily can be exploited in the new and promising instrument that
combines both the previously discussed techniques.
Mn was chosen primarly for its fundamental role in human biological processes and for a possible
combined MRI/PET that should have given a lot information in such applications like inestigation
in neural tract tracing [12], diagnosis and staging of pancreatic cancer (detection of β-cells) and in
general the need to follow stem cells’ position, dynamic and survival. [11]
MRI does not require unstable nuclei so the discussion is the same for both the isotopes; usually this
technique exploit the protons present in most of human tissue in order to perform clinical exams, even
though paramagnetic metals could improve it giving way better results. The most used paramagnetic
elements was gadolinium that shows very good properties but the search for now elements to be
exploited has started when it was observed that Gd induced a medical condition (in patients who
alrady have renal problems) known as nephrogenic systemic fibrosis (NSF) [9], that is a very harmful
side effect. Obviously this raised questions about its applicability in medical diagnosis using MRI and
this is why there’s been an increase in research of new paramagnetic elements that can be used as
contrast agents.
Figure 2. 
Figure 2.3: Differences in distributions between free ion Mn and DOTA chelates
Note: H, Heart; L, Liver; K, Kidneys; T, Tumor; Th, Thyroid
The most popular form used is manganese as free ion (MnCl2) and its relative technique is called
MEMRI (Manganese-Enhanced MRI); indeed manganese shows very good paramagnetic properties
when is oxidation number is 2 because of his high spin, id est his 5 unpaired electrons [10], that can
easily couple with the external induced magnetic field. Even though has shown very good results
in generating brighther signals [10] it has a quite heavy drawback: the ionic form of manganese is
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extremely toxic 5 and adding this information to its long biological life it is clear that its application
could be risky. This problem with free manganese seems to be avoided by using chelated manganese [9],
where the metal is linked through coordinate bonds to some ligands (usually organic compounds).
Basically the Mn ions cannot move free in the organism because of the macromolecules it is bond
to and several studies have made use of a molecule called DOTA (1,4,7,10 tetraazacyclododecane
1,4,7,10 tetraacetic acid) for its chelation stability with Mn(II) and for its widely spread utilization
in radiochemistry. [12] A great difference between free manganese and DOTA chelates is evident even
in their distribution as represented in Figure 2.3 where it is clear that the latter is well distributed in
the target region (tumoral cells) instead of free Mn that will execute its biological role (for example
is an important nutrient in mammals feeding) and concentrate in other region (image acquired with
a PET scan taken from [12]).
On the other hand, all these problems of administrated amount of manganese for MEMRI and its toxic
effect are completely avoided for PET application since a lower dose can be injected (many orders
of magnitude) while absolving its task as radiotracer and therefore being detectable [3]. Unstable
nuclei used in radiopharmaceuticals that will be then exploited for PET imaging should have some
basic requirements: low positron range (let’s say less than a mm) in order to have a very good spatial
resolution (for example in cases in which small structers need to be scanned); the radioactive nucleus
should decay to a stable one and there should be no prominent emissions of high energy γ during the
de-excitation of the daughter nucleus (to avoid other decays and further radiations in both cases) [8].
As for the isotopes of interest, 52Mn’s long half-life could be a double-edged knife6 while 51Mn’s
half-life is suitable for just one PET scan (time of the order of 18F ); on the contrary 52Mn has a very
good spatial resolution (positron emitted travels less than fluorine’s one) while the very high energetic
51Mn’s positron (> 2MeV ) makes very poor resoluted images. [4] [12]
5It has been observed that injected values above 10mg/kg of MnCl2/bodymass (that are tipically administered in
studies as bolus) are dangerous for the animal and may have long-term negative effects [3]
6Discussed previously, has both pros and cons: very usefull to acquire subsequent scans many days after the initial
injection but this increases the level of radiation absorbed
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Chapter 3
Dosimetric evaluation
We’ve seen that both isotopes of Mn shown before could be useful tools for PET and MRI but it is
also important to determine how much energy a radioactive nucleus transfers to the human body. A
radiation dose analysis is fundamental for diagnostic application of radiopharmaceuticals but clearly
this is not a measure that can be done directly, so it is necessary to develop methods to asses desired
values in order to gain information about the energy irradiated by a radionuclide. This is the purpose
of dosimetry, that despite its name (metry is related to experimental measures) concerns theoretical
calculations and models (often it is referred to as internal dosimetry when dealing with radiations from
inside the human body). A powerful tool in calculations of internal dose assessment (that will be used
in this work, too) is the OLINDA1/EXM [16] code version 1 which contains decay data for more than
800 radionuclides and weighting factors (for both emitted radiations and organs) as defined by the
ICRP (International Commision on Radiological Protection) 602 [14]; in detail, the job of OLINDA is
to compute DFs factors defined in 3.9 and, given the number of disintegrations N that occurred in
the source region, the equivalent dose HT of 3.10.
After having introduced some basic definitions of internal dosimetry, methods on how to compute
these quantities will be presented as well as appropriate changes in data acquired on animal (whereas
we are interested in human application). Afterwards all these tools will be used to perform a proper
dosimetric evaluation on human beings with two different methods, based respectively on data acquired
by Hernandez et al. [19] and by Graves et al. [4] on animal subjetcs using ionic form manganese.
All the informations about dosimetry in Nuclear Medicine have been taken from [13].
3.1 Basic concepts of dosimetry
First it is necessary to introduce a physical quantity that describes and quantify the radiation trans-
ferred to the absorber mean (the patient’s body) and this is the absorbed dose defined as the energy
absorbed per unit of mass:
D = dε
dm
(3.1)
The absorbed dose has the dimension of energy/mass and in the SI its unit is the gray (Gy) and
1Gy = 1 J/1 kg. Another important quantity is the equivalent dose that is defined as
HT,R = wRDT,R (3.2)
where wR is a weighting factor that takes in account the different possible damage dealt to the target
depending on the type of incident radiation (γ, alpha, proton, neutron, etc.) and it is dimensionless
and DT,R is the energy transferred by the radiation R to the tissue or organ T. This means that the
1Organ Level INternal Dose Assessment
2actually OLINDA code employs weigthing factors for human tissues that have been modified in ICRP 103 [17]
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unit of equivalent dose should be the same of absorbed dose and to highlight that they are different
quantities its unit is sievert (Sv) and values of wR are listed in Table 3.1.
Table 3.1: Weighting factors wR for different type of radiation as defined in ICRP 60 [14] (used in OLINDA
v.1) and in ICRP 103
Type of radiation ICRP 60 ICRP 103
Photons (all energies) 1 1
Electrons and muons (all energies) 1 1
Neutrons
< 10 keV 5
10 keV to 100 keV 10 A continous curve as
> 100 keV to 2MeV 20 a function of neutron energy
> 2MeV to 20MeV 10
> 20MeV 5
Protons 5 2
Alpha particles, fission fragments, heavy nuclei 20 20
One method to evaluate the term DT,R for internal dose assessment when a radioactive source is inside
the target region is the following (that is its time derivative, yet):
D˙T,R =
kA
∑
i yiEiφi
m
(3.3)
where k is just a numerical constant placed in order to have the dose expressed in the desired units (SI
or not), A is the activity of the radiation source defined as the number of disintegrations the occurs
per unit of time A = dNdt 3, Ei is the energy of the emitted radiation, yi is the number of radiations with
energy Ei that occurs per nuclear reaction, φi is the fraction of emitted energy absorbed by the target
and m is the mass of the target. Actually we are interested in computing its time-integral, indeed the
units of D˙ (in SI units) are Gy/s due to the presence of the activity and represents the absorbed dose
per unit of time. To know the total energy transferred we should know how many disintegration occurs
in the period of time in which the source is in the absorber medium and this is equivalent to compute
the integral of activity over time, whatever the function A(t), called time-activity curve, is. Obviously
we need to make some assumptions on the form of this unknown functions: at first we could consider
a case in which the activity decreases just by radioactive decay (exponential law) A(t) = A0e−λt and
the computation becomes trivial
A˜
A0
= 1
A0
∫ ∞
0
A(t) dt =
∫ ∞
0
e−λt dt = 1
λ
=
t1/2
ln 2 (3.4)
A˜ is called cumulated activity and has just been divided for its initial amount4 and this ratio is called
normalized cumulated activity; in the last passage the relationship between decay constant and half-
time was used to rewrite the result obtained as a function of a physical property of the radioactive
nucleus. At this point by just replacing A→ A˜/A0 and inserting all the decay informations required,
the absorbed dose can be computed. It’s important to note, though, that the integral just calculated
has the dimension of a time and in order not to get confused about its meaning, it has the unit of
Bq h/Bq.
However we can make a further assumption: usually the radiopharmaceuticals are excreted by the
organims, i.e. they have another way to “decay” that is related to biological processes and the simplest
(but that fits very well with experimental data) hypothesis is that it follows an exponential law, too.
So, given the biological decay X(t) = X0e−λbt its integral is the same as what computed before
3A is measured in Bq (becquerel) and 1Bq = 1 disintegration/1 s
4 so that the numerical value inserted in the absorbed dose formula does not depend on the number of administered
activity
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and considering the superpositions of these two decay mode (physical+biological) the effective decay
constant is λ = λp + λb. It may happen in practice that the biological life of radiopharmaceutical is
represented by a sum of exponential law (basically we are in the same assumptions stated before) in
the form X(t) = f1e−λ1t + ...+ fne−λnt and assuming also the physical decay the cumulated activity
is ∫ ∞
0
X(t) dt =
∫ ∞
0
e−λp(f1e−λ1t + ...+ fne−λnt) dt =
∑
i
fi
λp + λi
= 1ln 2
∑
i
fiTi (3.5)
it is easy to prove from λ = λp + λb that
T = TbTp
Tb + Tp
(3.6)
Whatever the hypothesis we use to describe the system and do the calculations (physical decay or
both physical and biological), we’ve derived a formula to calculate the absorbed dose in a very simple
situation. In reality, the radiation emitted in a tissue could escape from it and contribute to the
absorbed dose of another tissue so one just need to include all possible exchanges between tissues
or organs. Before generalizing this formula it’s necessary to mention that in the past years, many
researchers have grouped many factors in the formula of absorbed dose above or changed a bit some
definitions obtaining different equations that have the same meaning and lead to the same numerical
results. The notation that is going to be used is the one of the RADAR5 system that is
D = N ·DF (3.7)
where N is the number of disintegrations that occurs in the source region S and
DF = k
∑
i yiEiwiφi
m
(3.8)
is the dose factor (note that the addition of the weighting factor just gives as a result of the previous
calculation the equivalent dose and does not change the previous equations). By separating these two
terms it is more clear how to perform the calculations since the term N can be easily obtained from
experimental data as the time-activity curve’s integral while the dose factor DF needs to be calculated
starting from decay parameters and even Monte Carlo simulations in order to evaluate the terms φi
(fraction of energy released by the radiation in the medium). One important parameter that needs to
be evaluate in 3.8 is the mass of the organ that is being studied; this means that phantoms resembling
the human body are necessary in order to simulate different cases. A phantom is a mathematical
representation of the human body used to calculate Dose Factors. The OLINDA software has already
implemented 10 different phantoms (male and female adult, newborn, 4 phantoms spanning from 1
to 15 years old and 3 phantoms for pregnant woman); the one used here is the adult male phantom
(see Table 3.2) and was originally developed for the Medical Internal Radiation Dose Committee
(MIRD) of the Society of Nuclear Medicine; it is an approximation of the human body based on
simple geometrical shapes.
Now we can generalize to the case of target T and multiple sources S that is simply
DFS =
k
∑
i yiEiφi(T ← S)wi
mT
(3.9)
and therefore, adding up all the contributions from various sources to the same target, the resulting
equivalent dose
HT =
∑
S
NS ·DFS (3.10)
By the way it’s necessary to notice that the same equivalent dose to different organs or tissues may
be more dangerous to some with respect to others. This is why the ICRP introduced another physical
5RAdiation Dose Assessment Resource, an electronic resource that was created on the internet at the beginning of
this century in order to provide useful dose data worldwide
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Table 3.2: Mass values of adult male phantom present in OLINDA v.1
Tissue Masses (g)
Adrenals 16.3
Brain 1420
Breasts 351
Gallbladder Walls 10.5
Small Intestine 677
Stomach Wall 158
ULI Wall 220
Heart Wall 316
Kidneys 299
Liver 1910
Lungs 1000
Muscles 28000
Ovaries 8.7
Pancreas 94.3
Red Marrow 1120
Osteogenic Cells 120
Skin 3010
Spleen 183
Testes 3.91
Thymus 20.9
Thyroid 20.7
Urinary Bladder Wall 47.6
Uterus 79.0
Total Body 73700
quantity in order to consider these differences called effective dose [15] and it is defined, in a similiar
way to what it has been done for equivalent dose, as
E =
∑
T
HT · wT (3.11)
In this way the “relative radiosensitivity of each organ for expressing fatal cancers or genetic defects”
[13] is taken in account and it “represents the equivalent dose, which, if received uniformly by the
whole body, would result in the same total risk as that actually incurred by a given actual nonuniform
irradiation” [13]. The effective dose is used to compare the different doses that the same subject has
absorbed from different sources and it can be added to doses coming from other radiations in order
to quantify the total dose (for example when assessing the radiation intake after different medical
exams). Values of wT used by OLINDA are listed in Table 3.3 and are taken from [14], even though
new factors are available [17].
3.2 Dose assessment calculations
In order to perform dosimetry calculations is fundamental to know (given the radionuclide to study)
the disintegrations occured in the organs where the radiopharmaceuticals has accumulated. To do this
one needs to understand how it spreads all over the body and which organs have high concentration of
it, namely the biodistribution of the pharmaceutical. In this work it is going to be evaluated the dose
of MnCl2, that once injected it separates into Mn2+ and Cl−, thus the biodistribution of manganese
ions is needed.
There aren’t many researches in literature with good biodistribution data (measurements acquired in
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Table 3.3: Weighting factors for different organs as defined in ICRP 60 [14] and in ICRP 103 [17]
Organ ICRP 60 ICRP 103
Bone surfaces 0.01 0.01
Bladder 0.05 0.04
Brain // 0.01
Breast 0.05 0.12
Colon 0.12 0.12
Gonads 0.20 0.08
Liver 0.05 0.04
Lungs 0.12 0.12
Oesophagus 0.05 0.04
Red bone marrow 0.12 0.12
Salivary Gland // 0.04
Skin 0.01 0.01
Stomach 0.12 0.12
Thyroid 0.05 0.04
Remainder 0.05 0.12
Table 3.4: Biodistribution of 52Mn in various organs
All the values are in units of %ID (percentage of injected dose) and decay corrected, i.e. they
represents just biological elimination; S Gland data has not been used for dosimentric evaluations
since it is not present in OLINDA v.1
Time (h) Heart Liver Kidneys Muscle Pancreas Salivary Gland
1 7.50± 0.61 11.63± 1.12 18.30± 0.53 1.37± 0.12 18.30± 1.71 8.20± 0.92
3 6.70± 0.62 12.00± 1.41 18.57± 1.42 1.37± 0.06 18.23± 2.21 9.00± 1.35
12 4.30± 0.61 12.50± 0.69 17.47± 0.21 1.27± 0.15 17.43± 0.87 9.87± 0.49
24 3.33± 0.42 11.20± 0.72 16.33± 0.72 1.17± 0.12 17.23± 0.40 9.60± 0.30
72 2.83± 0.21 6.90± 0.46 11.83± 0.45 0.96± 0.15 15.70± 1.59 10.17± 0.37
120 2.57± 0.15 5.30± 0.10 9.27± 0.25 0.93± 0.06 13.03± 1.56 11.20± 0.85
168 2.47± 0.06 3.83± 0.29 7.00± 0.87 0.73± 0.07 10.63± 1.17 10.77± 0.71
216 2.30± 0.10 2.93± 0.15 5.57± 0.84 0.64± 0.05 8.07± 0.90 9.63± 0.32
264 2.07± 0.15 2.50± 0.10 4.57± 0.61 0.66± 0.02 6.43± 0.95 9.37± 0.55
312 1.93± 0.06 2.20± 0.10 4.03± 0.31 0.66± 0.05 5.90± 1.20 8.90± 0.26
limited intervals of time with respect to radionuclide’s half-life or very few samples); the best data
that have been found for this work has been recovered from Hernandez et al. [19] and Graves et al. [4]
and since these articles starts from different hypothesis and provides different data, different paths
will be followed for the internal dose assessment.
The purpose of the former is to show that 52Mn can be used for PET imaging of β − cells instead of
its use in MRI (due to its cytotoxic effect) and although Mn uptakes for some organs are reported (see
Table 3.4) no dosimetric evaluations have been done. All the values reported represent the activity
measured in a selected target region in vivo on animal via PET scans: this method affects the reliability
of the measures done because of the difficulty and uncertainty in selecting the region of interest from
which acquire 52Mn activity, especially on little areas. Moreover, it is important noticing that the
previous data were acquired from animals: dosimetric evaluations can be performed just by using
them or applying some changes to make them more suitable for human application. One of them is
the mass extrapolation: basically it consists in rescaling the data measured from mice to humans by
multiplying for a factor that takes into account the different percentage over the total body mass of
single organs
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(
%
organ
)
human
=
[(
%
gorgan
)
· (kgTB)
]
animal
·
(
gorgan
kgTB
)
human
(3.12)
The first term represents the percentage of total activity administered that would accumulate in the
human organ ,
( %
gorgan
)
animal
is the activity uptake in a particular organ divided by the mass of the
animal’s organ and the remaining terms are the mass of organs and total body of animal and human.
In the Hernandez’s experiment, the activity was measured using PET so the raw data are acquired
in the SUV unit (Standardized Uptake Value) defined as SUV =
(
%
gorgan
)
· (kgTB); in this unit the
previous formula becomes (
%
organ
)
human
= SUVanimal ·
(
gorgan
kgTB
)
human
(3.13)
From 3.13 it is possible to get the mass of the mice used in the experiment since Hernandez et al.
reports data both in SUV unit and %ID and so
SUV
%ID/g = massTB ≈ 28g (3.14)
Another possible correction to animal data that can be done is time extrapolation: basically it consists
in changing the istant of time at which the uptake was measured based on the different metabolism
of mice and humans and a simple empirical parametrization is given in [13]
thuman = tanimal
[
mh
ma
]1/4
(3.15)
Now it is possible calculating the effective dose for 52Mn starting from its biodistribution in Table
3.4. The organs taken into account (for which are reported significant uptake value) are liver, pan-
creas, kidneys, heart and muscle; salivary glands’ biodistribution is left out because there is not the
possibility to insert its disintegrations’ value in OLINDA v.1. All the data have been extrapolated
to human (with only mass correction and then with both mass and time corrections) and in order to
get information about the area underlying the points, the plot has been fitted with a sum of three
exponential6 decay f(t) =
3∑
i=1
fie
−λit that represent respectively the uptake,retention and elimination
of the radiopharmaceutical in the organ selected. The result of the fits are showed in Figure 3.1 and
the area of the fit function has been computed according to 3.5 because data are decay corrected and
therefore the physical decay constant needs to be added. The values obtained by integrating the pre-
vious distributions were then put in the OLINDA/EXM software together with the remaining activity
that it is accumulated in the rest of the body, whose distribution is unknown. To do so, there’s the
possibility in OLINDA to insert the value of the remaining activity so that it will be spread over all
other tissues in proportion to their mass. The remaining activity was calculated by assuming both
physical and biological decay (in order to consider all form of elimination of Mn from the body and
get more reliable results). Biological decay of Mn has been studied in [18] and it was found that it
can be described as the sum of two exponential decay that has a slow component of half-life equals to
39 days (about 70% of Mn is eliminated this way) and a fast component (for the remaining fraction)
of half life equals to 4 days. In the end, the total activity is
Atot
A0
=
∫ ∞
0
e−λp(0.7−λslowt + 0.3−λfastt) dt = 0.7
λp + λslow
+ 0.3
λp + λfast
(3.16)
6Exponentials are heavily used in this context: they are easy to integrate and they describes very well experimental
data
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and the remaining activity is simply calculated by subtracting the results of the area derived from
the fitted curves. All these calculations can be extended to 51Mn either, in fact it’s necessary to just
change the physical decay constant in the integrals above (both in 3.5 for the area under the curves
and in 3.16 for the assessment of the remaining activity) since biodistribution is the same for different
isotopes of an element.
The article of Graves S. A. et al. [4] deals with production, characterization by in vivo behavior and
preliminary dosimetric predictions of 51Mn and actually, in this case, there aren’t any biodistribution
data reported and thus disintegrations in source organs have already been computed by the authors
(see Table 3.5, central column). Even this time, the experiment has been conducted on animals but
this time no mass/time extrapolation or other methods have been used by Graves et al. [4]; also, since
the experiment involved 51Mn, uptake values in animals’ organs have been acquired for far less time
(up to ∼ 90min) than what has been done for 52Mn in [19] (13days). As a consequence, Graves et
al. have considered only physical elimination (i.e. radioactive decay) because of the relative quite
long biological elimination path. Thus, by multiplying 51Mn disintegrations for the ratio of the two
Mn isotopes’ half-lives it is possible to rescale the given data and perform a dosimetric evaluation for
52Mn even with this data (Table 3.5, right column).
Table 3.5: Numbers of disintegrations per unity of activity administered
All the data reported here are in units of MBq-h/MBq and the ones in central column are taken
from [4]
Tissue Numbers of 51Mn disintegrations Numbers of 52Mn disintegrations
Adrenals 0 0
Brain 4.43E-03 0.77
Breasts 0 0
Gallbladder Contents 0 0
LLI 0 0
Small Intestine 0 0
Stomach 0 0
ULI 6.42E-03 1.12
Heart Contents 0 0
Heart Wall 2.37E-02 4.13
Kidneys 6.91E-02 12.0
Liver 6.30E-02 11.0
Lungs 1.68E-02 2.93
Muscles 2.18E-03 0.38
Ovaries 0 0
Pancreas 4.11E-02 7.16
Red Marrow 0 0
Cortical Bone 8.40E-04 0.15
Trabecular Bone 0 0
Spleen 9.16E-03 1.60
Testes 0 0
Thymus 0 0
Thyroid 0 0
Urinary Bladder Contents 0 0
Uterus/Uterine Wall 0 0
Total Body 8.70E-01 152
17
3.3 Results
As for the first method described, based on Hernandez’s experiment, the data computed for 51Mn
and 52Mn have been inserted into OLINDA using adult male phantomand the relative effective doses
are listed in Table 3.6.
Table 3.6: Effective doses calculated for 51Mn and 52Mn with both the methods; all values are reported in
mSv/MBq
Isotope Herndandez’s data Graves’ data
Real Time Corrected Time
51Mn 1.12 · 10−2 1.13 · 10−2 1.24 · 10−2
52Mn 1.61 1.62 2.38
There is nearly no difference between time corrected and real time doses, so in this case the two
methods give essentially the same result. With the second method, so starting from Graves et al.
data, the effective dose of an adult male phantom for 52Mn is 2.38mSv/MBq whereas 51Mn’s one (
1.24 · 10−2mSv/MBq) calculated with OLINDA gives the same value the authors have found7. By
making a comparison between the effective dose obtained for 51Mn and 52Mn it is evident that the
second method produces higher values and this could be due to many factors: for example, Graves
et al. did not make use of mass extrapolation on animal data and have supposed only physical decay
without any biological elimination path that would have speed up its clearence from the body. On
the contrary, calculations based on biodistribution data acquired for longer period (the order of three
times the radionuclide’s half-life) should be preferable in order to take into account even biological
processes and have more reliable evaluations.
In Table 3.7 a comparison is presented between the dose absorbed of 52Mn by each target organ
for the two evaluations performed: nearly all the values computed starting from Graves et al. data
are higher than those obtained from Hernandez et al. except for brain. Considering that Mn plays
important biological roles in this organ and that this could lead to longer retention in them [12], this
underestimate could be due to the very short time the Mn biodistribution was measured by Graves
et al. with respect to Hernandez et al.
Just to have an idea of the order of magnitude of effective dose administered by radiopharmaceuticals
that are already being used in clinical practice, we could consider [18F ][FDG] that is a 18F -based
radiopharmaceutical which effective dose is 0.019mSv/MBq [14]. As expected, 52Mn transfers a
quite higher dose due to his long half-life and emissions of high energy photons, making it ill-suited
for clinical purpose in free ion form.
The only reference value found in literature, in order to make a comparison with the ones obtained in
these calculations, for 52Mn is in [8] and it is 0.924mSv/MBq that howewer has been derived assuming
very simplistic hypothesis: a complete uniform distribution in man and a biological elimination time
of Tb = 100h.
7actually in [4] it is computed the effective dose equivalent that is based on old ICRP 30 weigthing factor [15] while
in the table is reported the effective dose that is based on ICRP 60 [14] factors
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Table 3.7: Comparison of doses absorbed of 52Mn by target organs computed with OLINDA v.1
All values are in unit of mSv/MBq ; note that all values based on Graves et al. are higher than
their counterparts obtained from Hernandez’s biodistribution data except for brain
Tissue First method (Hernandez’s data) Second method (Graves’ data)
Adrenals 1.95 3.64
Brain 1.42 0.79
Breasts 1.18 1.77
Gallbladder Walls 2.14 3.49
LLI Wall 1.74 2.41
Small Intestine 1.96 2.97
Stomach Wall 1.79 3.35
ULI Wall 1.93 3.05
Heart Wall 1.78 4.25
Kidneys 2.42 9.13
Liver 2.49 3.62
Lungs 1.44 2.08
Muscles 1.26 1.72
Ovaries 1.79 2.50
Pancreas 2.78 13.4
Red Marrow 1.50 2.00
Osteogenic Cells 1.81 2.20
Skin 0.92 1.23
Spleen 1.75 4.48
Testes 1.29 1.72
Thymus 1.44 2.12
Thyroid 1.38 1.73
Urinary Bladder Wall 1.67 2.29
Uterus 1.83 2.59
Total Body 1.38 1.92
19
Time [h]
0 50 100 150 200 250 300
%
ID
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
 / ndf 2χ
 1.053 / 4
Prob   0.9016
    1f  0.3919
 1λ  0.001651
    2f  0.2909
 2λ  0.1229
    3f  0.2909
 3λ  0.1229
Heart
Time [h]
0 50 100 150 200 250 300
%
ID
1
2
3
4
5
6
7
8
9
10
 / ndf 2χ
 4.618 / 4
Prob   0.3287
    1f  0.2957
 1λ 0.003632− 
    2f  2.763
 2λ  0.00831
    3f  6.361
 3λ  0.008284
Liver
Time [h]
0 50 100 150 200 250 300
%
ID
6
8
10
12
14
16
 / ndf 2χ
 2.619 / 4
Prob   0.6234
    1f  0.9912
 1λ  0.03894
    2f  13.62
 2λ  0.003558
    3f  0.1073
 3λ 0.01028− 
Muscle
Time [h]
0 50 100 150 200 250 300
%
ID
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
2.2
2.4
 / ndf 2χ
 1.054 / 4
Prob   0.9015
    1f  0.009562
 1λ 0.007813− 
    2f  0.8873
 2λ  0.004131
    3f  1.232
 3λ  0.007909
Kidneys
Time [h]
0 50 100 150 200 250 300
%
ID
0.2
0.3
0.4
0.5
0.6
0.7
 / ndf 2χ
 2.739 / 4
Prob   0.6024
    1f  0.2254
 1λ  0.003778
    2f  0.2254
 2λ  0.003778
    3f  0.2254
 3λ  0.003778
Pancreas
Figure 3.1: Time-activity curves have been calculated and plotted for organs displaying relatively high uptake
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Chapter 4
Conclusions
MultiModal Imaging is a new tool in Nuclear Medicine that allows combining images with different
diagnostic contents. In order to do this it is necessary to find a radionuclide that could show both
good positron-emitting nuclear properties similar to 18F and high paramagnetic properties: a possible
isotope that satisfies these conditions is 52Mn. Various experiment have been carried out in order
to study its possible application, e.g. the METRICS experiment at the INFN Laboratori Nazionali
di Legnaro that aims at studying various aspects of the production of this radionuclide (possible
contaminants, alterative production routes, etc.). Therefore the goal of this work is to perform a
dosimetric assessment of the dose transferred to the human body by 52Mn-based radiopharmaceuticals.
Data used to perform the calculations have been taken from Hernandez et al. [19], that reports Mn
biodistribution up to 13 days post injection ofMnCl2, and from Graves et al. [4], that on the other hand
reports only disintegrations occured in source organs. These articles were chosen because have enough
measures to perform dose calculations even though present many critical issues: biodistribution data
taken from Hernandez et al. are obtained measuring the activity in vivo with PET scans and this could
lead to problems due to the difficulty in selecting small region (overlapping); ex vivo measurements of
the desired organ would be preferable and much more accurate than those reported. Instead, Graves
et al. acquired data on 51Mn measurements (t1/2 = 46.2min) and since it has a quite shorter half-life
than the time requested for biological elimination, only radioactive decay was assumed as elimination
path; furthemore, altough activity was measured on mice, no mass extrapolation correction for human
application has been done.
Subsequently internal dose calculations have been done and, although the assements based on the two
sets of data are a bit different different for the reasons showed before, 52Mn shows very high doses (for
example quite higher than [18F ][FDG]) as expected because of its long physical half-life combined with
long retention in organs. The latter contribution is due to Mn ions long biological half-life fromed after
the MnCl2 dissociated itself: of course better radiopharmaceutical should employs chelates in order
to prevent Mn ions formation and speeding up its elimination. Actually, no dosimetric evaluations
have been found in literature about the effective dose of 52Mn (except [8] that yet uses too simplistic
assumptions) so the results presented here should be considered as just a first step before successive
and more complete 52Mn studies (for example involving better radiopharmaceutical in order to avoid
Mn2+ formation or longer acquisition time for biodistribution measurements).
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